- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Climb Bio advances clinical trials with first patients dosed in key studies | 1 | Investing.com | ||
| 08.01. | Climb Bio, Inc.: Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 | 1.209 | GlobeNewswire (Europe) | First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved... ► Artikel lesen | |
| 08.01. | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.01. | Alumis wirft Climb Bio Vertragsbruch wegen verweigerter Meilensteinzahlung vor | 10 | Investing.com Deutsch | ||
| 31.12.25 | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| CLIMB BIO Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target | 2 | Investing.com | ||
| 18.12.25 | H.C. Wainwright hebt Kursziel für Climb Bio wegen Budoprutug-Fortschritten auf 11 US-Dollar an | 3 | Investing.com Deutsch | ||
| 18.12.25 | H.C. Wainwright raises Climb Bio stock price target to $11 on budoprutug progress | 2 | Investing.com | ||
| 11.12.25 | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.11.25 | Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 5 | GlobeNewswire (USA) | ||
| 06.11.25 | Climb Bio, Inc.: Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates | 141 | GlobeNewswire (Europe) | PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical... ► Artikel lesen | |
| 06.11.25 | Climb Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11.25 | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.25 | Climb Bio, Inc.: Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy | 272 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced... ► Artikel lesen | |
| 17.10.25 | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10.25 | Climb Bio, Inc.: Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 | 1 | GlobeNewswire (USA) | ||
| 16.10.25 | Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity | 1 | Benzinga.com | ||
| 16.10.25 | William Blair initiates coverage on Climb Bio stock with Outperform rating | 1 | Investing.com | ||
| 01.10.25 | Climb Bio beruft Susan Altschuller zur neuen Finanzvorständin | 3 | Investing.com Deutsch | ||
| 01.10.25 | Climb Bio taps Susan Altschuller as CFO | 1 | Seeking Alpha |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,95 | +0,60 % | BioNTech-Aktie: Hält das starke Momentum? | Die BioNTech-Aktie meldet sich 2026 eindrucksvoll zurück. Seit Jahresbeginn liegt der Titel um rund 23% im Plus, notiert bei knapp 120 US$ und zählt damit zu den auffälligen Gewinnern an der Börse.... ► Artikel lesen | |
| EVOTEC | 6,492 | +10,03 % | Evotec Aktie: Comebacktitel für 2026? | Aktionäre von Evotec müssen viel Geduld aufbringen. Seit Monaten scheitern immer wieder die Versuche der Biotech-Aktie, stabil über die 200-Tage-Linie zu springen. An oder knapp oberhalb des viel beachteten... ► Artikel lesen | |
| MEDIGENE | 0,054 | +13,03 % | Medigene: Zurückziehung - 18.11.2025 | ||
| MODERNA | 36,425 | +0,90 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| VALNEVA | 3,894 | -0,31 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 7,338 | -0,37 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| ILLUMINA | 120,22 | +0,45 % | Illumina, Inc.: Illumina completes acquisition of SomaLogic from Standard BioTools Inc. | Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 636,00 | -0,75 % | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q4 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) announced a profit for fourth quarter that Drops, from the same period last yearThe company's earnings totaled $844.6 million, or... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,420 | -1,39 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 25,390 | +0,10 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| BAVARIAN NORDIC | 26,500 | +3,43 % | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | ||
| INTELLIA THERAPEUTICS | 11,355 | +2,71 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,421 | -3,88 % | Unheilbar wird therapierbar: Diese Nano-Biotech-Aktie vor dem Durchbruch! | ||
| MICROBOT MEDICAL | 1,530 | +1,06 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| IMMUNITYBIO | 5,132 | -1,23 % | ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy |
CLIMB BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLIMB BIO INC finden Sie auf Wallstreet Online.